

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

NCT07466420

Status	RECRUITING
Phase	Not Applicable
Sponsor	Katerina M. Antoniou
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (2)

- Patients with an established diagnosis of IPF and Fibrotic ILD and will be eligible to participate in the study.
- The use of the approved standard of care antifibrotic therapy, either nintedanib or pirfenidone, and immunosuppressive therapy will be allowed as standard of care.

Exclusion (2)

- Subjects with a result of FeNO > 25 ppb will be excluded from the study to ensure that no other pulmonary diseases, such as asthma, are present.
- Patients who do not initiate quercetin within the first week after their baseline visit.

Locations (1 total)

Respiratory Department, University Hospital of Heraklion, School of Medicine, University of Crete, Heraklion, Crete, Greece